Clinical trials: Primary Breast Cancer, open to volunteers
Breast Cancer Survivor, Colorectal Cancer Survivors
Testing the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors
The goal of this study is to determine the feasibility of implementing a mobile health application for breast and colorectal cancer survivors following primary treatment.
- Trial name
- NCT07312786
- Testing
- virtual self-management intervention
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Nova Scotia Health Authority
Breast Cancer, Stage IV Breast Cancer
Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases
This is a national multicenter, prospective, randomized controlled trial. The study aims to compare the 5-year overall survival (OS) between patients receiving primary tumor surgery followed by systemic therapy (surgery group)…
- Conditions
- Breast Cancer, Stage IV Breast Cancer, Bone Metastases
- Trial name
- POSITIVE-Bone (NCT07687225)
- Testing
- Primary Tumor Resection, Standard systemic therapy
- Volunteers
- 216 people
- Sponsor
- West China Hospital
Breast Carcinoma
Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
This clinical trial develops and studies how well mobile health (m-Health) patient navigation (PN) strategies work to improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya.
- Trial name
- NCT07764796
- Testing
- Best Practice, Discussion, Interview - Stakeholder
- Where
- United States
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Emory University
Breast Cancer, Surgery
Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery
to analyze the feasibility for patients with early luminal breast cancer to be compliant with a diet modification - ketogenic or proteins restricted diet - during 9 +/- 1 days, before breast cancer surgery.
- Trial name
- MACS (NCT04469296)
- Testing
- iso-caloric ketogenic diet, protein restricted diet
- Where
- France
- Volunteers
- 75 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer
Preoperative Accelerated Partial Breast Irradiation in Patients With Locally Recurrent or Second Primary Breast Cancer
This study evaluates the acute toxicity and feasibility of repeat breast conserving therapy with preoperative accelerated partial breast re-irradiation (PAPBI) in female patients aged 51 years or older with ipsilateral recurrent…
- Trial name
- PAPBI-3 (NCT06362616)
- Testing
- Preoperative accelerated partial breast irradiation, Breast conserving surgery, Sentinel node procedure
- Where
- Netherlands
- Volunteers
- 31 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI…
- Trial name
- NCT05130801
- Testing
- pHLIP® ICG NIRF imaging
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer Female, Cardiometabolic Syndrome
Metabolic Flexibility and Autonomic Control After Muscle Power vs Metabolic Power Training in Postmenopausal Oncological Women: the POWER Health Study
POWER Health is a randomized clinical trial with a two-arm parallel design whose objectives are 1) to study metabolic flexibility and autonomic function (both capacities that describe cardiovascular health) in a sample of…
- Conditions
- Breast Cancer Female, Cardiometabolic Syndrome, Metabolism Disorder, Lipid, Autonomic Dysfunction
- Trial name
- POWER Health (NCT06336070)
- Testing
- HIIT program (8 weeks), MPI program (8 weeks)
- Where
- Spain
- Volunteers
- 56 people
- Sponsor
- University of Valencia
CCCA Assessed by Ki67 Drop Below <2.7% From Baseline
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
This is a multicenter, prospective, open-label, randomized phase II study to evaluate the CCCA assessed by Ki67 drop below \<2.7% from baseline to week 2 (window of opportunity) and to week 10 with capivasertib plus…
- Trial name
- NCT06607757
- Testing
- Capivasertib, Fulvestrant injection
- Where
- 25 sites in Germany
- Volunteers
- 120 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Axillary Lymph Node Metastasis
A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer
Through the research of this project, we expect to validate the clinical utility of the TuFEst-LN model in assessing axillary lymph node status in breast cancer patients.
- Trial name
- PRO-TuFEst-LN (NCT07304934)
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Abemaciclib, Abemaciclib-related Diarrhea
Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast Cancer
Remarkable progress has recently been made in the treatment of locally advanced, hormone receptor-positive, HER2-negative breast cancer with a high risk of recurrence, thanks to the addition of abemaciclib to endocrine therapy.
- Conditions
- Abemaciclib, Abemaciclib-related Diarrhea, Breast Cancer
- Trial name
- DOSABEMA (NCT07490509)
- Testing
- Blood samples for PK, Questionnaire
- Volunteers
- 235 people
- Sponsor
- Poitiers University Hospital
Breast Cancer Prevention
MELIORA Data Collection Campaigns
To support the development of the MELIORA digital app for the MELIORA main intervention, an initial pilot study (Data Collection Campaign, DCC) is being conducted with the three target participant groups: healthy women at…
- Trial name
- DCC (NCT07190066)
- Testing
- Data Collection campaign
- Where
- 7 sites in Greece, Lithuania and 2 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Harokopio University
Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Trial name
- ELUCIDATE (NCT05985655)
- Testing
- GTAEXS617, SoC
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 230 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Metastatic Breast Cancer, ER Positive Breast Cancer
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
This is a multi-center biomarkers study aiming to prospectively collect biological samples from patients with ER+ and HER2-negative metastatic breast cancer, who are candidate to first-line treatment with an aromatase inhibitor…
- Conditions
- Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer
- Trial name
- TIRESIAS (NCT04660435)
- Testing
- Thymidine kinase activity
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione Sandro Pitigliani
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Breast Cancer
A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients
Breast cancer is the most common malignant tumor in women. Recurrent or metastatic breast cancer is incurable. High risk patients usually have the following characteristics, such as, non-pCR after neoadjuvant therapy, lymph nodes…
- Trial name
- SMART (NCT03561740)
- Testing
- capecitabine
- Where
- China
- Volunteers
- 794 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Node-positive Breast Cancer
TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes
Due to high pathological complete remission (pCR) rates in both breast and lymph nodes (ypT0/Tis, ypN0) following neoadjuvant systemic therapy (NST) in many patients with initially clinically node-positive (cN+) breast cancer…
- Trial name
- SenTa2 (NCT05462457)
- Testing
- Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Kliniken Essen-Mitte
Breast Cancer
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer
Breast cancer (BC) is one of most prevalent malignant tumors in the world. According to the 2020 edition of the global cancer statistics report, the incidence rate of BC has overtaken lung cancer to become the most commonly…
- Trial name
- NCT05063136
- Testing
- Capecitabine+endocrine therapy
- Where
- China
- Volunteers
- 1,979 people
- Sponsor
- Henan Cancer Hospital
Endometrioid Ovarian Cancer, Primary Peritoneal Cancer
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer.
- Conditions
- Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT06856499
- Testing
- Cirtuvivint, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Breast Cancer Detection
FAP PET/CT for Staging Patients With Breast Cancer
This study aims to evaluate the clinical utility of [68Ga]Ga-FAP-2268 PET/CT for disease staging and assessment in patients with high-risk primary breast cancer.
- Trial name
- NCT07523607
- Testing
- 68Ga-FAP-2286
- Volunteers
- 65 people
- Sponsor
- Odense University Hospital
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech